WATERTOWN, Mass.–(BUSINESS WIRE)–Lyra Therapeutics, Inc., a clinical-stage biotechnology company
developing medicines precisely designed to target ear, nose and throat
(ENT) diseases, today announced that the company will present at the
Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019, at
9:00 a.m. ET. Maria Palasis, Ph.D., Lyra’s President and Chief Executive
Officer, will provide an overview of the company and a business update.
The Jefferies 2019 Healthcare Conference will be taking place June 4-7
in New York City.
About Lyra Therapeutics
Lyra Therapeutics is a clinical-stage biotechnology company developing
medicines precisely designed to target ear, nose and throat (ENT)
diseases, offering an alternative to conventional treatments or
surgeries. The company’s lead drug candidate, LYR-210, offers a novel
approach for directing anti-inflammatory medicine deep into sinonasal
tissues for up to six months of therapy. With proprietary expertise in
drug development and materials science, Lyra is applying its
transmucosal therapeutic system – comprised of drug administered through
a polymeric matrix – with the goal of enabling therapeutic action at the
site of inflammation in the sinonasal passages. Lyra Therapeutics is
located in Watertown, Massachusetts. For more information, please visit www.lyratx.com.
Contacts
Media Contact:
Kathryn Morris
Tel: 914-204-6412
kathryn@theyatesnetwork.com
Investor Contact:
Laurence Watts
Tel: 619-916-7620
laurence@gilmartinir.com